Page 59 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Predictive value of interim PET in DLBCL
85% (66-94) Predictive Negative (95% CI) Value
38% (21-57) Predictive * Positive Value (95% CI) 59% (43-74) Specificity (95% CI) Diagnostic information at 2 years 69% (42-87) Sensitivity (95% CI)
95% (85-98)
57% (41-72)
78% (67-86)
87% (68-95)
64% (39-84)
72% (49-88)
64% (39-84)
72% (49-88)
Abbreviations: 95% CI= 95% confidence interval, PFS=progression-free survival, NR=not reported, EFS= event-free survival, mo=months.
HR 95% CI Prognostic information univariate
53 g e e Cashen et al (2011) PFS Surviving: 33·9 24 (48·0%) 2·98 1·16 - 7·67 Zinzani et al (2011) EFS No events: 50 35 (38·5%) 3·94 1·69 - 9·19 Zhao et al(2007) PFS 27 (9-45) 18 (56·3%) 3·67 1·61 - 8·35 =extracted predictive test accuracy measures at two years survival prediction in Kaplan-Meier curve. = extracted from KM with numbers at risk =only available for complete patient cohort (16-44)
(12-68) =Tierney method based on number of events and P-value. = extracted from KM without numbers at risk.
= reply on request for additional information.
51 dd 52 cc fg
= reported in publication.
a
b
c
d
e
positive no (%) Interim PET
Median follow-up in months (range)
Results Outcome measure
Table 3 Continued
First author, year
57
3